Title: Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer
Authors: Crown, John P ×
Diéras, Véronique
Staroslawska, Elzbieta
Yardley, Denise A
Bachelot, Thomas
Davidson, Neville
Wildiers, Hans
Fasching, Peter A
Capitain, Olivier
Ramos, Manuel
Greil, Richard
Cognetti, Francesco
Fountzilas, George
Blasinska-Morawiec, Maria
Liedtke, Cornelia
Kreienberg, Rolf
Miller, Wilson H
Tassell, Vanessa
Huang, Xin
Paolini, Jolanda
Kern, Kenneth A
Romieu, Gilles #
Issue Date: Aug-2013
Publisher: Grune & Stratton
Series Title: Journal of Clinical Oncology vol:31 issue:23 pages:2870-8
Article number: 10.1200/JCO.2012.43.3391
Abstract: Metastatic breast cancer (MBC) remains an incurable illness in the majority of cases, despite major therapeutic advances. This may be related to the ability of breast tumors to induce neoangiogenesis, even in the face of cytotoxic chemotherapy. Sunitinib, an inhibitor of key molecules involved in neoangiogenesis, has an established role in the treatment of metastatic renal cell and other cancers and demonstrated activity in a phase II trial in MBC. We performed a randomized phase III trial comparing sunitinib plus capecitabine (2,000 mg/m2) with single-agent capecitabine (2,500 mg/m2) in patients with heavily pretreated MBC.
ISSN: 0732-183X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science